


(51) International Patent Classification:
C07K 16/10 (2006.01)(21) International Application Number:
PCT/US2022/030556(22) International Filing Date:
23 May 2022 (23.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/192,549 24 May 2021 (24.05.2021) US
63/265,032 06 December 2021 (06.12.2021) US
63/266,453 05 January 2022 (05.01.2022) US(71) Applicants: **VIR BIOTECHNOLOGY, INC.** [US/US];
499 Illinois Street, Suite 500, San Francisco, California
94158 (US). **HUMABS BIOMED SA** [CH/CH]; Via dei
Gaggini 3, 6500 Bellinzona (CH).(72) Inventors: **BARTHA, Istvan**; Via dei Gaggini 3, 6500
Bellinzona (CH). **CORTI, Davide**; Via dei Gaggini 3, 6500
Bellinzona (CH). **CZUDNOCHOWSKI, Nadine**; 499 Illi-nois Street, Suite 500, San Francisco, California 94158
(US). **SCHMID, Michael Alexander**; Via dei Gaggini
3, 6500 Bellinzona (CH). **SNELL, Gyorgy**; 499 Illinois
Street, Suite 500, San Francisco, California 94158 (US).
TELENTI, Amalio; 499 Illinois Street, Suite 500, San
Francisco, California 94158 (US).(74) Agent: **MORGAN, John, A.** et al.; Seed Intellectual Prop-
erty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seat-
tle, Washington 98104-7064 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(54) Title: ENGINEERED POLYPEPTIDES

**FIG. 290**

(57) Abstract: Provided herein are engineered polypeptides (e.g., Fc polypeptides, Fc polypeptide fragments, Fc fusion proteins, antibodies, and the like) that comprise a variant of an IgG Fc polypeptide (or a portion or fragment thereof), which variants (and the polypeptides that comprise these variants) have one or more improved characteristics over known Fc polypeptides.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

12 January 2023 (12.01.2023)